ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Aclidinium bromide is a long-acting muscarinic antagonist approved for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD). This 12-week phase III study evaluated efficacy and tolerability of aclidinium 200 or 400 μg in patients with moderate-to-severe COPD.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin Drug Investig

Title: Clinical drug investigation

Publisher: Springer Nature

ISSN (Electronic): 1179-1918

ISSN (Print): 1173-2563

Publication date (Electronic): Dec 2013

Volume: 33

Issue: 12

Affiliations

[1 ] Division of Pulmonary, Critical Care, Sleep and Allergy, 985910 Nebraska Medical Center, Omaha, NE, 68198-5910, USA, srennard@unmc.edu.

Article

DOI: 10.1007/s40261-013-0138-1

PubMed ID: 24085591

SO-VID: 9b854462-3094-4bd0-99a2-4bf42a121dc8

History

Data availability:

Comments

Comment on this article

scite_

Cited by 11

See all cited by